QUECTEL-WIRELESS
10.11.2022 10:01:40 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, announces that its industrial-grade 5G NR module RG500L-EU has gained GCF certification for operating on global 5G NR networks. The GCF certification means that the RG500L-EU module can help customers to efficiently deploy their 5G high-speed IoT devices worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109006142/en/
Quectel, a global IoT solutions provider, announces GCF certification for it's industrial-grade 5G NR module RG500L-EU (Photo: Business Wire)
Based upon the MediaTek T750 platform, the RG500L-EU integrates a 5G NR FR1 modem and a quadcore Arm Cortex-A55 processor. By leveraging the powerful CPU performance of the T750 chipset, customer devices can improve their device processing performance as well as enable significant cost optimization.
“The global certification by the GCF confirms our commitment to provide our customers with best-in-class IoT solutions, no matter where they are in the world,” said Dominikus Hierl, Senior Vice President Sales EMEA. “Quectel continues to drive IoT innovation, providing the very best in 5G modules and delivering the innovation our customers have come to expect in order to develop their 5G IoT applications.”
The module supports dual carrier aggregation (2CC CA) at 200MHz frequency band. This capability to combine available 5G spectrum assets can greatly improve signal coverage and transmission rates. Additionally, the RG500L-EU module can achieve a peak downlink rate of 4.67Gbps and a peak uplink rate of 1.25Gbps, bringing smooth and super-fast 5G speed experience to end users.
The RG500L-EU supports EasyMesh™ and WPA3 R3 encryption protocol, enabling IoT devices with more stable, cost-efficient and secure wireless connections. The module also offers flexible Wi-Fi configuration combinations, including single 5G 2x2 + 2.4G 2x2 dual-band, single 5G 4x4 + single 2.4G 4x4 dual-band, as well as single 5G 4x4 (5G high frequency band) + single 5G 4x4 (5G low frequency band) + single 2.4G 4x4 tri-band.
Featuring a compact design and low power consumption, the RG500L-EU can help customers to reduce time-consuming procedures including fixed network and equipment installation. Its rich peripheral interfaces including SGMII, PCIe and PCM give customers maximum flexibility in their IoT solution designs. In combination with Quectel’s unique QuecOpen platform, the RG500L-EU also improves customer terminal development efficiency and accelerates their time-to-market.
The RG500L-EU adopts an 8-antenna solution with four 2.7GHz antennas and four n77/n78 dedicated antennas to provide terminals with stronger and more stable signals as well as higher peak download rates. The module can additionally provide high gain antenna covering n78 band to help with signal reception.
In addition to the GCF certification, Quectel's 5G module RG500L-EU has also passed CE approval for the EU market as well as RCM approval for the Australian region. In the above areas, Quectel’s RG500L-EU module has already been chosen by customers to develop a variety of terminals including mobile hotspots, customer premise equipment (CPE), outdoor unit (ODU) and other 5G converged gateways and industrial gateways, which have been deployed in areas like industrial monitoring, remote collaboration, video conferencing, telemedicine, online education and many other fields.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109006142/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom